Behavioral treatment for alcohol use disorder in liver transplant patients
Contingency Management for Patients With Alcohol-Associated Liver Disease Following Liver Transplantation
This study is testing a new behavioral treatment to see if it helps liver transplant patients with alcohol use disorder reduce their drinking better than standard treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | University of California, Los Angeles Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT06304467 on ClinicalTrials.gov |
What this trial studies
This pilot randomized controlled trial investigates the effectiveness of a behavioral treatment called contingency management (CM) for patients with alcohol-associated liver disease (ALD) who have undergone liver transplantation. The study will enroll 30 participants, randomly assigning 15 to receive a 10-week CM intervention, which incentivizes reduced alcohol use, while the other 15 will receive standard treatment. Participants will be recruited through clinic visits and electronic medical records, ensuring a targeted approach to identify eligible candidates. The study aims to provide insights into the success of CM specifically for individuals with ALD, a population that has not been extensively studied in this context.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have received a liver transplant and have returned to drinking alcohol within the past 60 days.
Not a fit: Patients currently undergoing treatment for another substance use disorder or those unwilling to participate in behavioral treatment for alcohol use disorder may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide an effective behavioral intervention to help liver transplant patients with alcohol use disorder reduce their alcohol consumption and improve their overall health outcomes.
How similar studies have performed: While contingency management has shown effectiveness in other substance use disorders, this specific application for patients with alcohol-associated liver disease post-transplant is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects 18 years of age or older * Have received a liver transplant * Has documented return to drinking (subjective or objective) within the past 60 days * Willing to partake in behavioral treatment for AUD * Written informed consent and ability for subject to comply with the requirements of the study. Exclusion Criteria: * Current treatment for another substance use disorder * Unwilling to partake in behavioral treatment for AUD * Unwilling to provide written informed consent * Non-English speaking
Where this trial is running
Los Angeles, California
- Pfleger Liver Institute — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Arpan G Patel, MD — University of California, Los Angeles
- Study coordinator: Vanessa Ryan, MS
- Email: mdryan@mednet.ucla.edu
- Phone: (323) 833-4676
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.